clofibrate has been researched along with Cardiovascular Diseases in 32 studies
angiokapsul: contains clofibrate & insoitolnicotinate
Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Results of recent clinical trials on secondary prevention of ischemic heart disease indicate that judicious, long-term administration of adrenergic beta blockers and platelet-active drugs such as aspirin and Persantine (dipyridamole) would seem to yield protection against mortality associated with acute myocardial infarction, including sudden death." | 3.67 | Clinical trials on the efficacy of pharmacologic intervention reducing mortality from cardiovascular diseases. ( Borhani, NO, 1985) |
| "Identification and treatment of the metabolic syndrome is of enormous public health importance because it is associated with a marked elevation in coronary heart disease risk and affects nearly 25% of adults in the United States." | 2.42 | Fibrates for treatment of the metabolic syndrome. ( Maki, KC, 2004) |
| "Metabolic syndrome is associated with increased cardiovascular risk." | 2.41 | [Fibrate influence on lipids and insulin resistance in patients with metabolic syndrome]. ( Idzior-Waluś, B, 2001) |
| "Hypertriglyceridemia has been recently recognized as a vascular risk factor, based on both clinical and experimental findings." | 2.38 | Pharmacological control of hypertriglyceridemia. ( Franceschini, G; Paoletti, R, 1993) |
| "From 30 cases of mixed hyperlipidemia which were resistant to apparently correctly managed treatment, combining an adapted diet and Clofibrate, the authors confirmed that there is no specific clinical or laboratory picture in these cases: except for the constant presence of two beta-lipoproteins, with a high percentage of slow pre-beta, on electrophoresis on agarose, persisting throughout the length of inactive treatment." | 1.25 | [Mixed hyperlipidemia resistant to ordinary dietetic and medical treatment. 30 cases]. ( De Gennes, JL; Lambrozo, J; Truffert, J; Turpin, G, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 20 (62.50) | 18.7374 |
| 1990's | 5 (15.63) | 18.2507 |
| 2000's | 4 (12.50) | 29.6817 |
| 2010's | 3 (9.38) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sando, KR | 1 |
| Knight, M | 1 |
| Wang, D | 1 |
| Liu, B | 1 |
| Tao, W | 1 |
| Hao, Z | 1 |
| Liu, M | 1 |
| Oliver, MF | 1 |
| Manktelow, B | 1 |
| Gillies, C | 1 |
| Potter, JF | 1 |
| Maki, KC | 1 |
| Birgens, HS | 1 |
| Hansen, MS | 1 |
| Lamm, G | 1 |
| Heller, F | 1 |
| Hartwig, W | 1 |
| Wójcicki, J | 1 |
| Franceschini, G | 1 |
| Paoletti, R | 1 |
| Boumendil, EF | 1 |
| Knopp, RH | 1 |
| Linton, MF | 1 |
| Fazio, S | 1 |
| Idzior-Waluś, B | 1 |
| Deglin, SM | 1 |
| Deglin, JM | 1 |
| Chung, EK | 1 |
| Holzgreve, H | 1 |
| De Gennes, JL | 1 |
| Turpin, G | 1 |
| Lambrozo, J | 1 |
| Truffert, J | 1 |
| Clagett, GP | 1 |
| Collins, GJ | 1 |
| Wedel, H | 1 |
| Vedin, A | 1 |
| Wilhelmsen, L | 1 |
| Gantmacher, ML | 1 |
| Dunnigan, MG | 1 |
| Hughes, MD | 1 |
| Pocock, SJ | 1 |
| Borhani, NO | 1 |
| Saheta, NP | 1 |
| Spesivtseva, VG | 1 |
| Kakhnovskiĭ, IM | 1 |
| Dorokhova, AS | 1 |
| Al'bert, LB | 1 |
| Schwandt, P | 1 |
| Cagãnovă, A | 1 |
| Cagăn, S | 1 |
| Anet, P | 1 |
| Brouns, H | 1 |
| Delescluse, A | 1 |
| Malcolm, J | 1 |
| Van den Abbeele, KG | 1 |
14 reviews available for clofibrate and Cardiovascular Diseases
| Article | Year |
|---|---|
Nonstatin therapies for management of dyslipidemia: a review.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, | 2015 |
Fibrates for secondary prevention of cardiovascular disease and stroke.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Bezafibrate; Cardiovascular Diseases; Caus | 2015 |
Interventions in the management of serum lipids for preventing stroke recurrence.
Topics: Cardiovascular Diseases; Clofibrate; Estrogens, Conjugated (USP); Humans; Hypolipidemic Agents; Prav | 2002 |
Fibrates for treatment of the metabolic syndrome.
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Clofibrate; Fenofibrate; Gemfibrozil; Humans; Hyp | 2004 |
[Prevention of thrombosis by thrombocyte inhibition. 2. Clinical results].
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Cerebrovascular Disorders; Clofibrate; Dextrans; | 1980 |
The cardiovascular disease programme of WHO/EURO. A critical review of its first 12 years.
Topics: Adult; Cardiovascular Diseases; Clinical Trials as Topic; Clofibrate; Coronary Disease; Double-Blind | 1981 |
Pharmacological control of hypertriglyceridemia.
Topics: Body Weight; Cardiovascular Diseases; Clofibrate; Exercise; Fatty Acids, Omega-3; Humans; Hypertrigl | 1993 |
Drug treatment of lipid disorders.
Topics: Anion Exchange Resins; Cardiovascular Diseases; Clofibrate; Female; Humans; Hydroxymethylglutaryl-Co | 1999 |
Re-emergence of fibrates in the management of dyslipidemia and cardiovascular risk.
Topics: Angiography; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; | 2000 |
[Fibrate influence on lipids and insulin resistance in patients with metabolic syndrome].
Topics: Cardiovascular Diseases; Clofibrate; Fenofibrate; Hemostasis; Humans; Hyperinsulinism; Hyperlipidemi | 2001 |
Drug-induced cardiovascular diseases.
Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Antidepressive Agents, Tricyclic; Antihypertensive A | 1977 |
Platelets, thromboembolism and the clinical utility of antiplatelet drugs.
Topics: Animals; Aspirin; Blood Coagulation Factors; Blood Platelets; Cardiovascular Diseases; Clofibrate; F | 1978 |
Antiplatelet agents: a review.
Topics: Angina Pectoris; Aspirin; Blood Platelets; Cardiovascular Diseases; Cerebrovascular Disorders; Clofi | 1979 |
Iatrogenic cardiovascular disease (an aspect of preventive cardiology).
Topics: Abnormalities, Drug-Induced; Analgesics; Anti-Arrhythmia Agents; Anti-Bacterial Agents; Antidepressi | 1968 |
4 trials available for clofibrate and Cardiovascular Diseases
| Article | Year |
|---|---|
The cardiovascular disease programme of WHO/EURO. A critical review of its first 12 years.
Topics: Adult; Cardiovascular Diseases; Clinical Trials as Topic; Clofibrate; Coronary Disease; Double-Blind | 1981 |
A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators.
Topics: Adult; Cardiovascular Diseases; Cholelithiasis; Cholesterol; Clinical Trials as Topic; Clofibrate; C | 1978 |
[Increased mortality with clofibrate].
Topics: Adult; Cardiovascular Diseases; Clinical Trials as Topic; Clofibrate; Double-Blind Method; Humans; M | 1979 |
Within-subject diastolic blood pressure variability: implications for risk assessment and screening.
Topics: Adult; Age Factors; Analysis of Variance; Bayes Theorem; Blood Pressure; Cardiovascular Diseases; Ch | 1992 |
15 other studies available for clofibrate and Cardiovascular Diseases
| Article | Year |
|---|---|
Cholesterol-lowering and cancer in the prevention of cardiovascular disease.
Topics: Cardiovascular Diseases; Clofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperch | 2010 |
Consensus conference: Treatment of hypertriglyceridemia.
Topics: Body Weight; Cardiovascular Diseases; Clofibrate; Gemfibrozil; Humans; Hyperlipidemias; Hyperlipopro | 1984 |
[Should clofibrate still be prescribed?].
Topics: Adult; Animals; Cardiovascular Diseases; Cholesterol; Clofibrate; Cricetinae; Humans; Hyperlipoprote | 1982 |
[Various therapeutic advances].
Topics: Anticoagulants; Cardiovascular Diseases; Cimetidine; Clofibrate; Digoxin; Narcotics; Peptic Ulcer; P | 1981 |
[Current data on adverse effects of clofibrate].
Topics: Biliary Tract Diseases; Cardiovascular Diseases; Chemical and Drug Induced Liver Injury; Clofibrate; | 1980 |
Mortality from non-cardiovascular disease and diabetes mellitus.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cause of Death; Clofibrate; Diabetes Mellitus; Fr | 1998 |
[Clofibrate: revocation of the revocation].
Topics: Cardiovascular Diseases; Clofibrate; Germany, West; Humans; Legislation, Drug | 1979 |
[Mixed hyperlipidemia resistant to ordinary dietetic and medical treatment. 30 cases].
Topics: Adult; Aged; Cardiovascular Diseases; Clofibrate; Female; Glucose; Humans; Hyperlipidemias; Lipoprot | 1975 |
Should clofibrate still be prescribed?
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Clofibrate; Humans; Hyperlipidemias | 1992 |
Clinical trials on the efficacy of pharmacologic intervention reducing mortality from cardiovascular diseases.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Clofibrate; | 1985 |
[Therapeutic use of miscleron in patients with diabetes mellitus and cardiovascular disorders].
Topics: Adolescent; Adult; Age Factors; Aged; Cardiovascular Diseases; Clofibrate; Diabetes Complications; D | 1973 |
[Hyperlipoproteinemias: significance--diagnosis--therapy].
Topics: Adolescent; Adult; Blood Protein Disorders; Cardiovascular Diseases; Child; Child, Preschool; Choles | 1971 |
Cardio-vascular disease and public health.
Topics: Australia; Cardiovascular Diseases; Clofibrate; Coronary Disease; Humans; Prognosis; Public Health; | 1972 |
[Effects of long-term administration of Clofibrate Spofa on serum lipid level].
Topics: Adult; Aged; Cardiovascular Diseases; Clofibrate; Coumarins; Drug Interactions; Female; Humans; Lipi | 1972 |
Primary prevention of atherosclerotic cardiovascular disease among Sabena flying personnel.
Topics: Aerospace Medicine; Arteriosclerosis; Cardiovascular Diseases; Clofibrate; Humans; Hypercholesterole | 1972 |